MarketPulse
N

$NTRA

4 articles found
3 positive
0 negative
1 neutral
BenzingaBenzinga··Vandana Singh

Natera Positioned to Capture $20B MRD Market as Testing Adoption Accelerates

William Blair initiates Natera coverage, citing $1B MRD revenue in 2025 with 40%+ growth expected in 2026 as penetration rises.
NTRAmarket opportunitycompetitive advantage
BenzingaBenzinga··Vandana Singh

Natera's Signatera Test Offers Path to Surgery-Free Breast Cancer Treatment

Natera's MRD test shows older breast cancer patients may avoid surgery. Study demonstrates perfect detection rates, boosting NTRA stock 5.26% to $196.68.
NTRAbreast cancerSignatera
The Motley FoolThe Motley Fool··James Halley

Exelixis Expands Beyond Cabozantinib With FDA Approval and Robust Pipeline

Exelixis secures FDA approval for zanzalintinib and expands beyond cabozantinib with robust pipeline, posting 57.9% EPS growth while advancing multiple Phase 3 trials.
MRKNTRAEXELFDA approvalbiotech
The Motley FoolThe Motley Fool··Lee Samaha

Druckenmiller's Portfolio Reflects Conviction in Growth and AI Exposure

Druckenmiller concentrates holdings in Natera and TSMC, betting on genetic diagnostics growth and AI-driven semiconductor demand while balancing near-term profitability with long-term structural tailwinds.
TSMNTRAcapital expendituresemiconductor